Tokyo - Delayed Quote JPY

Taiko Pharmaceutical Co.,Ltd. (4574.T)

Compare
385.00 -4.00 (-1.03%)
At close: 3:15 PM GMT+9
Currency in JPY All numbers in thousands
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
6,492,000.00
6,120,000.00
5,040,000.00
10,720,000.00
17,683,989.00
Cost of Revenue
3,287,000.00
3,543,000.00
3,961,000.00
7,973,000.00
5,263,129.00
Gross Profit
3,205,000.00
2,577,000.00
1,078,000.00
2,746,000.00
12,420,859.00
Operating Expense
3,332,000.00
3,583,000.00
4,157,000.00
7,694,000.00
6,769,871.00
Operating Income
-127,000.00
-1,006,000.00
-3,079,000.00
-4,948,000.00
5,650,988.00
Net Non Operating Interest Income Expense
23,000.00
17,000.00
-5,000.00
-3,000.00
6,415.00
Pretax Income
-2,347,000.00
-3,563,000.00
-4,869,000.00
-8,887,000.00
5,374,270.00
Tax Provision
-15,000.00
47,000.00
25,000.00
706,000.00
1,522,711.00
Net Income Common Stockholders
-2,333,000.00
-3,611,000.00
-4,895,000.00
-9,594,000.00
3,851,559.00
Diluted NI Available to Com Stockholders
-2,333,000.00
-3,611,000.00
-4,895,000.00
-9,594,000.00
3,851,559.00
Basic EPS
-49.65
-76.25
-112.26
-220.52
89.18
Diluted EPS
-49.65
-76.25
-112.26
-220.52
88.82
Basic Average Shares
49,785.00
47,360.00
43,602.00
43,509.00
43,188.60
Diluted Average Shares
50,193.71
47,360.00
43,602.00
43,509.00
43,363.65
Total Operating Income as Reported
-127,000.00
-1,005,000.00
-3,079,000.00
-4,947,000.00
5,650,987.00
Total Expenses
6,619,000.00
7,126,000.00
8,118,000.00
15,667,000.00
12,033,000.00
Net Income from Continuing & Discontinued Operation
-2,333,000.00
-3,611,000.00
-4,895,000.00
-9,594,000.00
3,851,559.00
Normalized Income
-210,651.47
-1,833,848.00
-4,583,192.00
-7,948,306.40
3,906,114.81
Interest Income
31,000.00
25,000.00
5,000.00
3,000.00
6,697.00
Interest Expense
8,000.00
8,000.00
10,000.00
6,000.00
282.00
Net Interest Income
23,000.00
17,000.00
-5,000.00
-3,000.00
6,415.00
EBIT
-2,339,000.00
-3,555,000.00
-4,859,000.00
-8,881,000.00
5,374,552.00
EBITDA
-1,858,000.00
-2,851,000.00
-4,122,000.00
-7,940,000.00
5,847,423.00
Reconciled Cost of Revenue
3,287,000.00
3,543,000.00
3,961,000.00
7,973,000.00
5,263,129.00
Reconciled Depreciation
481,000.00
704,000.00
737,000.00
941,000.00
472,871.00
Net Income from Continuing Operation Net Minority Interest
-2,333,000.00
-3,611,000.00
-4,895,000.00
-9,594,000.00
3,851,559.00
Total Unusual Items Excluding Goodwill
-2,136,000.00
-2,314,000.00
-406,000.00
-2,372,000.00
-76,089.00
Total Unusual Items
-2,136,000.00
-2,314,000.00
-406,000.00
-2,372,000.00
-76,089.00
Normalized EBITDA
278,000.00
-537,000.00
-3,716,000.00
-5,568,000.00
5,923,512.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
-13,651.47
-536,848.00
-94,192.00
-726,306.40
-21,533.19
12/31/2020 - 3/18/2009

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers